4.7 Article

A Structural Biology Approach Enables the Development of Antimicrobials Targeting Bacterial Immunophilins

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 58, Issue 3, Pages 1458-1467

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01875-13

Keywords

-

Funding

  1. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200700057C, HHSN272201200025C]
  2. UK Ministry of Defence
  3. German Research Foundation (DFG) via the Collaborative Research Center [630 (SFB630)]
  4. Office of Science, Office of Basic Energy Sciences, of the U. S. Department of Energy [DE-AC02-05CH11231]
  5. National Institutes of Health, National Institute of General Medical Sciences
  6. Howard Hughes Medical Institute

Ask authors/readers for more resources

Macrophage infectivity potentiators (Mips) are immunophilin proteins and essential virulence factors for a range of pathogenic organisms. We applied a structural biology approach to characterize a Mip from Burkholderia pseudomallei (BpML1), the causative agent of melioidosis. Crystal structure and nuclear magnetic resonance analyses of BpML1 in complex with known macrocyclics and other derivatives led to the identification of a key chemical scaffold. This scaffold possesses inhibitory potency for BpML1 without the immunosuppressive components of related macrocyclic agents. Biophysical characterization of a compound series with this scaffold allowed binding site specificity in solution and potency determinations for rank ordering the set. The best compounds in this series possessed a low-micromolar affinity for BpML1, bound at the site of enzymatic activity, and inhibited a panel of homologous Mip proteins from other pathogenic bacteria, without demonstrating toxicity in human macrophages. Importantly, the in vitro activity of BpML1 was reduced by these compounds, leading to decreased macrophage infectivity and intracellular growth of Burkholderia pseudomallei. These compounds offer the potential for activity against a new class of antimicrobial targets and present the utility of a structure-based approach for novel antimicrobial drug discovery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available